Denmark's Pharmaceutical Sector and Its Economic Impact
Introduction
The pharmaceutical industry in Denmark has experienced rapid growth in recent years. Since 2005, the real gross value added (GVA) of pharmaceuticals has increased sixfold, driven primarily by increased export demand for new weight-loss drugs developed by Novo Nordisk, the leading pharmaceutical company in Denmark.
Key Characteristics
- Rapid Growth: The real GVA of pharmaceuticals has surged, reflecting significant export demand for new drugs.
- Merchanting and Processing (M&P): Danish large multinational enterprises (MNEs) have become increasingly reliant on M&P, with a notable increase in exports that do not cross borders. This is particularly pronounced in the pharmaceutical sector, where the value of drugs is heavily dependent on intellectual property.
- Labor Productivity: Labor productivity in the pharmaceutical sector has more than tripled since 2005, compared to a 20% increase across all industries.
Empirical Analysis
To understand the impact of productivity shocks in the pharmaceutical sector on the Danish economy, the analysis focuses on Novo Nordisk and its effects on other firms within and outside the industry.
Productivity Shocks and Economic Growth
- Weak Correlation: Empirical evidence shows weak correlations between productivity shocks at Novo Nordisk and overall economic growth, as well as between Novo Nordisk’s productivity and that of other firms.
- Industry Spillovers: Despite the weak correlation, there is significant evidence of within-industry spillover effects in the pharmaceutical sector.
Organization of the Chapter
- Stylized Facts: Summarizes key facts about the Danish pharmaceutical sector and its macroeconomic impact.
- Empirical Models and Results: Presents the empirical models and results of the analysis.
- Conclusions: Concludes the chapter by summarizing findings and implications.
Box 1: Danish Exports That Do Not Cross Borders
Danish companies' exports that do not cross borders are becoming increasingly important. These exports are classified as merchanting and processing, depending on whether the companies own the intermediate inputs. The foreign production has higher labor productivity and lower employee compensation, suggesting that national aggregate labor productivity growth may not fully reflect domestic productivity growth.
Conclusion
This chapter highlights the rapid growth and significant impact of the pharmaceutical sector on Denmark's economy, emphasizing the importance of understanding productivity shocks and their spillovers within the industry.
